Nautilus Biotechnology, Inc.
NAUT· Nasdaq
NAUTNautilus Biotechnology, Inc.
Filed Jul 30, 2024 · 10-Q · 30 days after period end · 0001808805-24-000058
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$18.01M | -$15.81M | -$14.69M | -$10.71M |
| EPS Diluted | -$0.14 | -$0.13 | -$0.12 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Jul 30, 2024 · 30 d after period end
